A Long-term Follow-up Study of Pulmonary Function Changes Using Phase-resolved Functional Lung MRI in Patients With COVID-19

• Sponsor: Beijing Chao Yang Hospital (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT05933317
• Collaborator: (none)
• Enrollment: 150
• Location: 1
• Anticipated Duration (Months): 24
• Patients Per Site Per Month: 6.3

Study Details

Study Description

Brief Summary

So far, the number of COVID-19 infections worldwide has exceeded 700 million. Long-term damage to the lungs is a major sequela of COVID infection. Pulmonary function testing is an important means for the evaluation of lung damage. MRI examinations with free breathing and no contrast agent can prevent patients from suffering from ionizing radiation damage caused by multiple CT examinations.

Condition or Disease	Intervention/Treatment	Phase
Pulmonary Function	Diagnostic Test: Functional lung MRI

Study Design

• Study Type: Observational
• Anticipated Enrollment: 150 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: A Long-term Follow-up Study of Pulmonary Function Changes Using Phase-resolved Functional Lung MRI in Patients With COVID-19
• Actual Study Start Date: Jan 1, 2023
• Anticipated Primary Completion Date: Dec 31, 2023
• Anticipated Study Completion Date: Dec 31, 2024

Outcome Measures

Primary Outcome Measures

1. QDP, VDP [6 months]

   perfusion defect percentage, ventilation defect percentage

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 90 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Older than 18 years; Sign the informed consent; Patients diagnosed with COVID-19 by nucleic acid test and survived to be discharged; Complete clinical data during hospitalization.

Exclusion Criteria:

• Patients with bacterial pneumonia; Patients with MRI contraindications.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Beijing Chaoyang Hospital	Beijing	Beijing	China	100020

Sponsors and Collaborators

• Beijing Chao Yang Hospital

Investigators

• Study Chair: Tao Ouyang, Dr., Beijing Chao Yang Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Tao Ouyang, Beijing Chao Yang Hospital, Beijing Chao Yang Hospital
• ClinicalTrials.gov Identifier: NCT05933317
• Other Study ID Numbers: 202212301
• First Posted: Jul 6, 2023
• Last Update Posted: Jul 6, 2023
• Last Verified: Jul 1, 2023

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Study Results

No Results Posted as of Jul 6, 2023